Information for patients
We are moving from promise to practice in the clinic.View our clinical trials
SGN-CD19A is an antibody-drug conjugate (ADC) targeting CD19, a protein expressed on acute lymphoblastic leukemia and some types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), as well as on certain healthy cells of the immune system. We have reported preclinical data demonstrating that SGN-CD19A effectively binds to target cells, internalizes and induces potent cell-killing activity and durable tumor regressions at low doses in multiple cancer models.
SGN-CD19A is in phase 1 clinical trials for CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Based on encouraging phase 1 data, a phase 2 trial in relapsed DLBCL is planned.